NYSE:BIO.B - Get Free Report ) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th.
Get Bio-Rad Laboratories alerts:
Sign Up
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report ) last announced its earnings results on Thursday, February 15th. The company reported $3.10 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million for the quarter.
Bio-Rad Laboratories Stock Down 3.9 % Shares of BIO.B traded down $10.96 during trading on Tuesday, reaching $268.95. The company's stock had a trading volume of 135 shares, compared to its average volume of 87. The company has a fifty day moving average of $326.03 and a two-hundred day moving average of $316.86. Bio-Rad Laboratories has a twelve month low of $271.00 and a twelve month high of $467.95. The company has a market cap of $7.67 billion, a price-to-earnings ratio of -13.03 and a beta of 0.66. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.
Bio-Rad Laboratories Company Profile (
Get Free Report )
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Featured Articles
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
